Clinical Trial Update: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Pirtobrutinib plus Venetoclax and Rituximab (PVR) versus Venetoclax and Rituximab (VR) in previously treated chronic lymphocytic leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Loxo Oncology, Inc. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING